美股详情

本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

The Nightview Fund

26.07

-0.8062-3.00%

成交量：344.00

成交额：8,943.02

市值：2,199.70万

市盈率：- -

高：26.07

开：26.07

低：26.07

收：26.88

数据加载中...

总览公司新闻公告

公司资料

公司名字：

The Nightview Fund

交易所：

ARCA

成立时间：

2018

员工人数：

- -

公司地址：

10900 Hefner Pointe Drive,Suite 400,Oklahoma City,Oklahoma,United States

官网：

http://www.nightstartx.com

邮编：

73120

电话：

传真：

405-896-5825

简介：

Nightstar Therapeutics Plc最初于2013年5月根据英格兰和威尔士的法律成立，随后于2014年1月更名为NightstaRx Limited。该公司是一家领先的临床阶段基因治疗公司，专注于开发和治疗药物患有罕见的遗传性视网膜疾病，否则会进入失明。利用他们在眼科，基因治疗和药物开发方面的专业知识，他们正在开发一系列专有产品候选人，旨在大幅度修改或停止目前尚未批准的治疗的遗传性视网膜疾病的进展。他们的任务是维护和通过构建领先的垂直整合视网膜基因治疗公司，恢复患者的视力。

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/NITE/company"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NITE","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NITE\",,,,,undefined,":{"symbol":"NITE","market":"US","secType":"STK","nameCN":"The Nightview Fund","latestPrice":26.07,"timestamp":1746028155205,"preClose":26.8762,"halted":0,"volume":344,"delay":0,"floatShares":843768,"shares":843768,"eps":0,"marketStatus":"交易中","change":-0.8062,"latestTime":"04-30 11:56:23 EDT","open":26.07,"high":26.07,"low":26.07,"amount":8943.022352,"amplitude":0,"askPrice":26.3,"askSize":1400,"bidPrice":26.27,"bidSize":1400,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1746043200000},"marketStatusCode":2,"adr":1,"adrRate":1,"listingDate":1506571200000,"exchange":"ARCA","adjPreClose":26.8762,"sharesOutstanding":843768,"nav":26.63,"aum":22466502.19,"bidAskSpread":0,"preHourTrading":{"tag":"盘前","latestPrice":26.88,"preClose":26.8762,"latestTime":"09:11 EDT","volume":1,"amount":26.88,"timestamp":1746018715468},"volumeRatio":0.442692},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NITE\",,,,,undefined,":{"symbol":"NITE","floatShares":843768,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.442692,"shares":843768,"dividePrice":0,"high":26.07,"amplitude":0,"preClose":26.8762,"low":26.07,"week52Low":22.21,"pbRate":"--","week52High":31.89,"institutionHeld":0,"latestPrice":26.07,"eps":0,"divideRate":0,"volume":344,"delay":0,"ttmEps":0,"open":26.07,"prevYearClose":29.87,"prevWeekClose":26.646,"prevMonthClose":26.3266,"prevQuarterClose":26.3266,"fiveDayClose":25.3031,"twentyDayClose":26.6134,"sixtyDayClose":30.7342},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{"companyId":1858671235,"yearFounded":2018,"address":"10900 Hefner Pointe Drive,Suite 400,Oklahoma City,Oklahoma,United States","zipCode":"73120","officePhone":"405-778-8377","officeFax":"405-896-5825"},"stockCompanyDetail":{"websiteUrl":"http://www.nightstartx.com","stockEarnings":[{"period":"1week","weight":0.0986},{"period":"1month","weight":0.0185},{"period":"3month","weight":-0.1294},{"period":"6month","weight":0.0233},{"period":"1year","weight":0.0714},{"period":"ytd","weight":-0.1002}],"compareEarnings":[{"period":"1week","weight":0.0513},{"period":"1month","weight":-0.0024},{"period":"3month","weight":-0.0789},{"period":"6month","weight":-0.0252},{"period":"1year","weight":0.0868},{"period":"ytd","weight":-0.0542}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Nightstar Therapeutics Plc最初于2013年5月根据英格兰和威尔士的法律成立，随后于2014年1月更名为NightstaRx Limited。该公司是一家领先的临床阶段基因治疗公司，专注于开发和治疗药物患有罕见的遗传性视网膜疾病，否则会进入失明。利用他们在眼科，基因治疗和药物开发方面的专业知识，他们正在开发一系列专有产品候选人，旨在大幅度修改或停止目前尚未批准的治疗的遗传性视网膜疾病的进展。他们的任务是维护和通过构建领先的垂直整合视网膜基因治疗公司，恢复患者的视力。","exchange":"ARCA","name":"The Nightview Fund","nameEN":"The Nightview Fund"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"NITE\",market:\"US\",,,undefined,":null,"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NITE\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NITE\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NITE\",market:\"US\",delay:false,,,undefined,":{}}}